CME Session 3
Cardiovascular Committee
Sunday, September 10, 15:00-16:30

Session Title
Nuclear Imaging in Cardiac Amyloidosis – What Else?

Chairpersons
Samia Massalha (Haifa, Israel)
Christoph Rischpler (Stuttgart, Germany)

Programme
15:00 - 15:20 Maria Papathanasiou (Essen, Germany): Background and novel therapies
15:20 - 15:45 Olivier Lairez (Toulouse, France): Bone scan – all you need to know.
15:45 - 16:10 Dario Genovesi (Pisa, Italy): PET – do we really need it?
16:10 - 16:30 Hendrea Tingen (Groningen, Netherlands): Nuclear imaging for therapy response.

Educational Objectives
1. Gain a deep insight into the disease of amyloidosis and in particular the cardiac involvement of amyloidosis.
2. Become familiar with the nuclear imaging modalities available for the diagnosis of cardiac amyloidosis.
3. To learn the appropriate use of diagnostic options in cardiac amyloidosis (keyword: diagnostic algorithm).
4. To independently make the correct diagnosis of cardiac amyloidosis on the basis of case studies.
5. To learn the possibilities of quantification of SPECT and PET.

Summary
This CME session aims to give the attendee a comprehensive understanding of the clinical picture of cardiac amyloidosis, the current treatment options and the use of nuclear medicine imaging procedures. The participants will be informed about the general significance of cardiac amyloidosis, the various, partly unspecific and also 'red flag' symptoms and the current and future therapy options. The problem of the sometimes-difficult diagnosis will also be discussed. The importance of bone scintigraphy in diagnostics within the framework of current guidelines is another important topic. An insight into the possibilities of PET imaging for diagnosis is also given. Finally, the possible role of nuclear medicine imaging in evaluating the response to therapy is discussed.

Key Words
cardiac amyloidosis; bone scan; amyloid PET; transthyretin